Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia

BACKGROUND: The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents. METHODS: To determine if cenersen merits testing in larger efficacy studies, an exploratory study of cenersen in combination with idarubicin either alone...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Cortes, J, Kantarjian, H, Ball, E D, DiPersio, J, Kolitz, J E, Fernandez, H F, Goodman, M, Borthakur, G, Baer, Maria R, Wetzler, Meir
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4977021/
https://ncbi.nlm.nih.gov/pubmed/21717444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26292
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires